Model evaluation Individual predictions vs
Compared to pregnancies not exposed to NSAIDs, NSAID use accounted for a 14 percent higher risk for birth defects, 29 percent higher risk for low birth weight, and a 9 percent higher risk of oligohydramnios
Do not stop semaglutide without consulting your provider, as chills often resolve within days as your body adapts
Newer agents like tirzepatide (a dual GLP-1/GIP receptor agonist) offer enhanced efficacy if semaglutide alone hasn't met your goals, but this represents optimization rather than discontinuation
Going lower risks metabolic adaptation, where your body downregulates metabolism to match the reduced intake, creating the plateau that frustrates so many GLP-1 users
GLP1R attenuates sympathetic response to high glucose via carotid body inhibition